NLS Pharma AG announced this week successful results of its ADHD clinical trial using Mazindol, a non-stimulant. The adult-focused study found that while the drug is not a traditional stimulant treatment of adult attention deficit hyperactive disorder (ADHD), treatment outcomes were similar to those using a stimulant. The use of stimulants to treat ADHD has been linked to abuse, poor toleration, and death in some cases. Non-stimulant treatments for this disease have been highly sought for both adults and children. Read the full press release here.